Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Interim Report – Q1-Q3, 2021

11/11/2021 | 06:57am EST

Interim Report - Q1-Q3, 2021

November 2021

2

Forward-looking statements

Certain information set forth and given in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-

looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates' business, projects and joint ventures; (iii) execution of ViroGates' vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates' projects; (v) completion of ViroGates' projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates' current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of

ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Contents

Summary4

Management review

8

Financial statements

13

Statement by the Board and 23

Executive Management

3

On 11 November 2021, the Board of Directors has accepted the interim report for the third quarter of 2021 (the period 1 July - 30 September 2021) for ViroGates A/S.

The interim report is unaudited.

4

Contents

Summary

4

Management review

8

Financial statements

13

Statement by the Board and

23

Executive Management

5

Revenue increased by 66% in Q1-Q3, 2021, compared to last year - Q3

revenue was lower than recent quarters due to hospital vacation periods

Financial results in Q1-Q3, 2021

(Q1-Q3, 2020 results in brackets)

  • Revenue increased by 66% to TDKK 5,063 (TDKK 3,055)
  • Operating expenses increased by 8% to TDKK -19,354 (TDKK -17,862)
  • Operating loss decreased by -3% to TDKK -14,455 (TDKK -14,974)
  • Net loss decreased by -5% to TDKK -13,641 (TDKK -14,293)
  • Cash and cash equivalents at the end of the period amounted to TDKK 17,475 (TDKK 38,032)

"We continue to see revenue growth compared to the same period last year. The revenue in Q3 was lower than previous quarters due to the seasonal effect from the summer vacation and fewer COVID-19-related tests due to fewer patients. Although emergency department sales activities have been hindered by the COVID-19 pandemic, we still expect to become cash flow positive with the existing cash at hand."

Mark Christian Hvidberg da Silva, CFO

Mark da Silva

TDKK+66%

Revenue 3,055 5,063

Operating

-3%

loss

-14,455

-14,974

-54%

38,032

17,475

Cash

balance

Q1-Q3, 2020

Q1-Q3, 2021

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

ViroGates A/S published this content on 11 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2021 11:56:12 UTC.


ę Publicnow 2021
All news about VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More news
Financials
Sales 2020 5,35 M 0,82 M 0,82 M
Net income 2020 -18,7 M -2,87 M -2,87 M
Net cash 2020 33,5 M 5,13 M 5,13 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 507 M 77,7 M 77,6 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float -
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S11.11%78
EXACT SCIENCES CORPORATION0.77%13 515
GUARDANT HEALTH, INC.-22.44%7 886
BGI GENOMICS CO., LTD.11.15%6 529
ADAPTIVE BIOTECHNOLOGIES CORPORATION-31.04%2 731
INVITAE CORPORATION-23.12%2 658